Abstract
Preliminary findings demonstrate that patients with rectal cancer receiving radiotherapy with a combination of capecitabine and oxaliplatin have better local regional control compared with those receiving capecitabine plus radiotherapy. This article presents interim data from the ongoing phase 3 open-label Adjuvant Treatment of Concurrent R and CAPOX or Capecitabine Alone for Stage II and III Rectal Cancer trial [NCT00714077].
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
